Introduction
Colon capsule endoscopy (CCE) is increasingly recognized as a patient-centered, minimally invasive alternative to traditional colonoscopy, particularly in incomplete procedures or colonic pathology detection settings1. The OMOM colon capsule (OMOM CC; Jinshan Science & Technology (Group) Co., Ltd., China)2 enables pan-enteric imaging and integrates advanced technology to optimize pathology detection and patient usability. This investigator-led, multinational study evaluated its real-world performance across four European centres, including the feasibility of remote procedure.
Aims & Methods
This prospective observational study included 119 adult patients referred for CCE. Clinical indications included gastrointestinal (GI) bleeding (iron-deficiency anaemia, positive faecal occult blood), inflammatory bowel disease (IBD) evaluation (including suspected or monitoring known IBD), and colorectal surveillance (for polyps and post-cancer follow-up). Bowel preparation protocol included laxatives, boosters and prucalopride (where available). All video studies were centrally interpreted by trained readers at CorporateHealth International ApS (CHI). Capsule ingestion was performed at home in one centre using a nurse-supervised smart receiver system (InteliGI Smartbox, CHI). Primary endpoints were examination completion and pathology detection rates. Secondary endpoints included safety and patient-reported experience.
Results
Among the 119 patients (mean age 52.6), 65M /54F. The most common indications were: GI bleeding (n=49), IBD-related (n=37), colorectal surveillance (n=30). Pathology was detected in the colon in 61%, the small bowel in 29.4%, and at either site in 71.2% of patients. In the subgroup receiving prucalopride (72.3% of cases), examination completion increased to 81.7%. The completion rate for the 11 patients with a previously incomplete colonoscopy was 90.9%. In 16.0% of patients, headaches and/or nausea were reported; however, no serious complications were reported. Patient acceptability was high: over 80% of respondents were satisfied with the procedure and would accept the same method again. 84% of patients would opt for the remote procedure again, indicating strong acceptance of the decentralised, home-based model and supporting its feasibility for wider adoption.
Conclusion
The OMOM CC system demonstrated robust diagnostic performance and high patient acceptability in a real-world, multinational cohort. High pathology detection rates in both small bowel and colon, particularly among patients with prior incomplete colonoscopy. A remote procedure model with centralized interpretation by trained readers supports scalable integration into pathways for lower GI diagnostics.
References
1. Koulaouzidis A, Baatrup G. Current status of colon capsule endoscopy in clinical practice. Nat Rev Gastroenterol Hepatol. 2023;20:557-558. doi: 10.1038/s41575-023-00783-2.
2.https://www.jinshangroup.com/product/omom-cc-colon-capsule-endoscopy-system/
Disclosure
This study was fully supported by JINSHAN Science & Technology Ltd, the manufacturer of the OMOM CC. The sponsor had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors had full access to all data and take full responsibility for the integrity of the data and the accuracy of the analysis.